GW&K Investment Management LLC decreased its stake in Celgene Co. (NASDAQ:CELG) by 4.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 113,589 shares of the biopharmaceutical company’s stock after selling 4,908 shares during the period. GW&K Investment Management LLC’s holdings in Celgene were worth $14,134,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in the company. SG Americas Securities LLC boosted its stake in Celgene by 175.9% in the third quarter. SG Americas Securities LLC now owns 91,485 shares of the biopharmaceutical company’s stock valued at $9,563,000 after buying an additional 212,007 shares in the last quarter. PICTET BANK & TRUST Ltd boosted its position in Celgene by 16.5% in the third quarter. PICTET BANK & TRUST Ltd now owns 35,445 shares of the biopharmaceutical company’s stock valued at $3,705,000 after buying an additional 5,025 shares in the last quarter. Headinvest LLC purchased a new position in Celgene during the fourth quarter valued at $2,667,000. Sawgrass Asset Management LLC purchased a new position in Celgene during the third quarter valued at $31,970,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in Celgene by 3.1% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 346,882 shares of the biopharmaceutical company’s stock valued at $36,260,000 after buying an additional 10,568 shares in the last quarter. Hedge funds and other institutional investors own 77.68% of the company’s stock.
Celgene Co. (NASDAQ:CELG) opened at 123.27 on Friday. The firm has a market cap of $95.90 billion, a PE ratio of 49.51 and a beta of 1.74. Celgene Co. has a 12-month low of $94.42 and a 12-month high of $127.64. The company has a 50-day moving average price of $124.35 and a 200-day moving average price of $116.33.
Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, January 26th. The biopharmaceutical company reported $1.61 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.59 by $0.02. The company earned $2.98 billion during the quarter, compared to the consensus estimate of $3.03 billion. Celgene had a return on equity of 77.95% and a net margin of 17.80%. Celgene’s revenue was up 16.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.18 EPS. On average, equities analysts predict that Celgene Co. will post $7.23 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Celgene Co. (CELG) Shares Sold by GW&K Investment Management LLC” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.tickerreport.com/banking-finance/2484463/celgene-co-celg-shares-sold-by-gwk-investment-management-llc.html.
CELG has been the subject of several research analyst reports. Cann restated a “buy” rating on shares of Celgene in a report on Thursday, January 26th. Cantor Fitzgerald restated a “buy” rating and set a $159.00 price target on shares of Celgene in a report on Friday, January 6th. Cowen and Company restated an “outperform” rating and set a $150.00 price target on shares of Celgene in a report on Thursday, January 12th. Mizuho set a $130.00 price target on Celgene and gave the company a “buy” rating in a report on Sunday, February 19th. Finally, Vetr cut Celgene from a “strong-buy” rating to a “buy” rating and set a $131.49 target price for the company. in a report on Tuesday, January 17th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-four have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $139.46.
In other news, Director Gilla Kaplan sold 14,033 shares of the business’s stock in a transaction on Thursday, March 30th. The shares were sold at an average price of $123.83, for a total transaction of $1,737,706.39. Following the completion of the sale, the director now directly owns 73,109 shares of the company’s stock, valued at approximately $9,053,087.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Rupert Vessey sold 4,000 shares of the business’s stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $124.42, for a total transaction of $497,680.00. Following the sale, the insider now directly owns 778 shares of the company’s stock, valued at $96,798.76. The disclosure for this sale can be found here. 0.97% of the stock is owned by insiders.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with MarketBeat.com's FREE daily email newsletter.